Krystal Biotech, Inc.
For the period ended Mar 31, 2026. Filed May 4, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 4, 2026
KRYS$306.50+1.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets as of and
Condensed Consolidated Balance Sheets
| (in thousands, except par value) | March 31,2026 | December 31,2025 |
|---|---|---|
| Assets | ||
| Current assets | ||
| Cash and cash equivalents | $501,313 | $496,304 |
| Short-term investments | 322,092 | 331,487 |
| Accounts receivable, net | 127,022 | 127,425 |
| Inventory | 42,646 | 40,475 |
| Prepaid taxes | 10,642 | 14,006 |
| Prepaid expenses and other current assets | 16,026 | 14,905 |
| Total current assets | 1,019,741 | 1,024,602 |
| Property and equipment, net | 153,582 | 150,776 |
| Long-term investments | 193,485 | 128,066 |
| Right-of-use assets | 7,035 | 7,239 |
| Deferred tax asset, net of valuation allowance | 22,824 | 22,824 |
| Other non-current assets | 300 | 287 |
| Total assets | $1,396,967 | $1,333,794 |
| Liabilities and Stockholders’ Equity | ||
| Current liabilities | ||
| Accounts payable | $4,089 | $3,238 |
| Current portion of lease liability | 1,800 | 1,771 |
| Accrued rebates | 70,717 | 58,181 |
| Accrued expenses and other current liabilities | 31,196 | 39,752 |
| Total current liabilities | 107,802 | 102,942 |
| Lease liability | 7,312 | 7,568 |
| Other long-term liabilities | 5,124 | 3,724 |
| Total liabilities | 120,238 | 114,234 |
| Commitments and contingencies (see note 7) | ||
| Stockholders’ equity | ||
| Common stock; $0.00001 par value; 80,000 shares authorized as of March 31, 2026 and December 31, 2025; 29,437 and 29,192 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively. | — | — |
| Additional paid-in capital | 1,198,257 | 1,194,261 |
| Accumulated other comprehensive (loss) gain | (1,623) | 1,136 |
| Retained earnings | 80,095 | 24,163 |
| Total stockholders’ equity | 1,276,729 | 1,219,560 |
| Total liabilities and stockholders’ equity | $1,396,967 | $1,333,794 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.